CD8A and neoplasm: Consequently, MSI-H/dMMR–CRC patients already show restricted TCR diversity in regard to CD8+ T cells equipped with tumor specificity at the baseline, with these tumor-specific T cell clones rapidly expanding following ICI treatment [3].